Association between metabolic syndrome and menopausal symptoms in perimenopause
Archives of Public Health · 15.07.2026 · 18 (1)
DOI: 10.3889/aph.2026.6656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Public Health, online erschienen am 15.07.2026. Verfasst von Aneta Sima und 4 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The perimenopausal transition is characterized by hormonal fluctuations that trigger physical and psychological symptoms while simultaneously increasing the risk of metabolic syndrome. Understanding the link between these physiological shifts is crucial for preventing long-term cardiovascular and endocrine complications. Aim of the study was to determine the prevalence of metabolic syndrome (MS) in perimenopausal women and evaluate the association between the severity of menopausal symptoms and MS components. Materials and methods: This prospective cohort study was conducted over a one- year period (2021-2022) at the University Clinic for Gynaecology and Obstetrics. The study included 100 perimenopausal patients (aged 45–50) with abnormal uterine bleeding, categorized by BMI: group I (BMI > 30), group II (BMI up to 30), and a control group (n=40) of asymptomatic women. Data were collected via the Menopause Quick 6 assessment tool and laboratory biochemical analyses (lipid status, glycemia, blood pressure, and anthropometric measurements).
Results
The prevalence of metabolic syndrome was significantly higher in patients of group I (80.3%) and group II (41.2%) compared to the control group (17.5%). While MS prevalence was similar between premenopausal (52.9%) and perimenopausal (52.8%) patients, specific symptoms showed strong statistical correlations. In group I (p < 0.05), metabolic syndrome and hot flashes, insomnia, and bone pain were significantly associated. In group II, insomnia remained significantly associated with MS (p = 0.0326). Hot flashes were the most prevalent symptom in group I (93.9%), while insomnia predominated in group II (73.5%).
Conclusion
The study demonstrates a significant link between the intensity of menopausal symptoms - particularly vasomotor symptoms and sleep disturbances - and the prevalence of metabolic syndrome. These findings suggest that severe menopausal symptoms may serve as early clinical indicators of metabolic risk. An integrated clinical approach addressing both hormonal shifts and metabolic health is essential for reducing long-term cardiovascular and diabetic risks in perimenopausal women.
Zitieren
APA
Sima, A., Daneva-Markova, A., Simeonova-Krstevska, S., Livrinova, V., & Dabeski, D. (2026). Association between metabolic syndrome and menopausal symptoms in perimenopause. Archives of Public Health, 18(1). https://doi.org/10.3889/aph.2026.6656
Vancouver
Sima A, Daneva-Markova A, Simeonova-Krstevska S, Livrinova V, Dabeski D. Association between metabolic syndrome and menopausal symptoms in perimenopause. Archives of Public Health. 2026;18(1). doi:10.3889/aph.2026.6656
BibTeX
@article{Sima2026,
author = {Sima, Aneta and Daneva-Markova, Ana and Simeonova-Krstevska, Slagana and Livrinova, Vesna and Dabeski, Drage},
title = {Association between metabolic syndrome and menopausal symptoms in perimenopause},
journal = {Archives of Public Health},
year = {2026},
volume = {18},
number = {1},
doi = {10.3889/aph.2026.6656}
}
EUVIMED